GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nascent Biotech Inc (OTCPK:NBIO) » Definitions » Net Margin %

NBIO (Nascent Biotech) Net Margin % : 0.00% (As of Jun. 2024)


View and export this data going back to 2011. Start your Free Trial

What is Nascent Biotech Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. Nascent Biotech's Net Income for the three months ended in Jun. 2024 was $-0.38 Mil. Nascent Biotech's Revenue for the three months ended in Jun. 2024 was $0.00 Mil. Therefore, Nascent Biotech's net margin for the quarter that ended in Jun. 2024 was 0.00%.

The historical rank and industry rank for Nascent Biotech's Net Margin % or its related term are showing as below:


NBIO's Net Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -140.3
* Ranked among companies with meaningful Net Margin % only.

Nascent Biotech Net Margin % Historical Data

The historical data trend for Nascent Biotech's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nascent Biotech Net Margin % Chart

Nascent Biotech Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Net Margin %
Get a 7-Day Free Trial - -127.87 -47.00 - -

Nascent Biotech Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Nascent Biotech's Net Margin %

For the Biotechnology subindustry, Nascent Biotech's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nascent Biotech's Net Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nascent Biotech's Net Margin % distribution charts can be found below:

* The bar in red indicates where Nascent Biotech's Net Margin % falls into.



Nascent Biotech Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Nascent Biotech's Net Margin for the fiscal year that ended in Mar. 2024 is calculated as

Net Margin=Net Income (A: Mar. 2024 )/Revenue (A: Mar. 2024 )
=-2.088/0
= %

Nascent Biotech's Net Margin for the quarter that ended in Jun. 2024 is calculated as

Net Margin=Net Income (Q: Jun. 2024 )/Revenue (Q: Jun. 2024 )
=-0.377/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Nascent Biotech  (OTCPK:NBIO) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.


Nascent Biotech Net Margin % Related Terms

Thank you for viewing the detailed overview of Nascent Biotech's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Nascent Biotech Business Description

Traded in Other Exchanges
N/A
Address
631 US Hwy 1, Suite 407, N Palm Beach, FL, USA, 33408
Nascent Biotech Inc is a United States-based clinical-stage biopharmaceutical company. The company is focused on the development and delivery of human antibodies and cytokine responses to the treatment of cancer. The company's products include Pritumumab, CLNH5, and MultiPharm. The company is engaged in the development of Pritumumab which would be used for the treatment of brain cancer and pancreatic cancer. The company is also exploring the use of Pritumumab against other viruses.
Executives
Lowell Thomas Holden director, officer: CFO 631 US HWY 1, SUITE 407, NORTH PALM BEACH FL 33408
Sean Carrick director, officer: President 631 US HWY 1, SUITE 407, NORTH PALM BEACH FL 33408
Brandon Price director, officer: Senior VP Business Development 6330 NANCY RIDGE DR., SUITE 105, SAN DIEGO CA 92121
Douglas John Karas director 631 US HWY 1, SUITE 407, NORTH PALM BEACH FL 33408
Mark Glassy director, officer: CEO 6330 NANCY RIDGE DR., SUITE 105, SAN DIEGO CA 92121